---
title: "Sanofi halts atopic dermatitis development of amlitelimab, drops global filing plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293705733.md"
description: "Sanofi has halted the clinical development of amlitelimab for moderate-to-severe atopic dermatitis and dropped global filing plans following a strategic review. The decision stems from an unfavorable efficacy-safety assessment, with the drug deemed not a meaningful advance over standard care despite durable responses in Phase 3 trials. Sanofi's 2026 financial guidance remains unchanged, while a Phase 2 study for celiac disease continues, with results expected in the second half of 2026."
datetime: "2026-07-24T05:30:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293705733.md)
  - [en](https://longbridge.com/en/news/293705733.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293705733.md)
generator: "portal-rs"
---

# Sanofi halts atopic dermatitis development of amlitelimab, drops global filing plans

-   Sanofi halted clinical development of amlitelimab for moderate-to-severe atopic dermatitis. \* Plans to skip global regulatory filings following a strategic review of its development portfolio. \* Decision reflects an unfavorable overall efficacy-safety assessment to date. \* Long-term Phase 3 ESTUARY extension showed durable response, but the drug was not seen as a meaningful advance over standard care. \* 2026 financial guidance unchanged; Phase 2 celiac disease study continues with results expected in 2H 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240130OMX\_\_\_\_\_CNEWS\_FR\_GNW1001214208\_fr) on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SNY.US](https://longbridge.com/en/quote/SNY.US.md)
- [SNYNF.US](https://longbridge.com/en/quote/SNYNF.US.md)

## Related News & Research

- [Sanofi Drops Dupixent Successor Candidate After Assessing Data](https://longbridge.com/en/news/293787328.md)
- [Sino Biopharma rebrands global operations under SBP Group identity](https://longbridge.com/en/news/296347598.md)
- [Zevra Therapeutics presents long-term real-world MIPLYFFA data in Niemann-Pick type C at SSIEM 2026](https://longbridge.com/en/news/296905592.md)
- [Ecopipam Priority Review Could Be A Game Changer For Teva Pharmaceutical Industries (TEVA)](https://longbridge.com/en/news/296688992.md)
- [Sagimet advances AURORA Phase 3 acne trial of denifanstat, targets Q4 2026 enrollment](https://longbridge.com/en/news/296901945.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**